OncoCyte (FRA:7OC0) FCF Margin % : -1,452.43% (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is OncoCyte FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. OncoCyte's Free Cash Flow for the three months ended in Dec. 2023 was €-4.18 Mil. OncoCyte's Revenue for the three months ended in Dec. 2023 was €0.29 Mil. Therefore, OncoCyte's FCF Margin % for the quarter that ended in Dec. 2023 was -1,452.43%.

As of today, OncoCyte's current FCF Yield % is -62.11%.

The historical rank and industry rank for OncoCyte's FCF Margin % or its related term are showing as below:

FRA:7OC0' s FCF Margin % Range Over the Past 10 Years
Min: -5209.6 Med: -1987.41 Max: -1552.37
Current: -1552.37

During the past 11 years, the highest FCF Margin % of OncoCyte was -1552.37%. The lowest was -5209.60%. And the median was -1987.41%.

FRA:7OC0's FCF Margin % is ranked worse than
94.64% of 224 companies
in the Medical Diagnostics & Research industry
Industry Median: -11.09 vs FRA:7OC0: -1552.37

OncoCyte FCF Margin % Historical Data

The historical data trend for OncoCyte's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoCyte FCF Margin % Chart

OncoCyte Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-2,236.50

-1,737.63

-5,211.62

-1,570.90

OncoCyte Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-3,808.88	-3,261.37	-1,476.81	-526.62	-1,452.43

Competitive Comparison of OncoCyte's FCF Margin %

For the Diagnostics & Research subindustry, OncoCyte's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OncoCyte's FCF Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, OncoCyte's FCF Margin % distribution charts can be found below:

* The bar in red indicates where OncoCyte's FCF Margin % falls into.

OncoCyte FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

OncoCyte's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-21.647	/	1.378
	=	-1,570.90 %

OncoCyte's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-4.183	/	0.288
	=	-1,452.43 %

OncoCyte FCF Margin % Related Terms

Thank you for viewing the detailed overview of OncoCyte's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

OncoCyte (FRA:7OC0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » OncoCyte Corp (FRA:7OC0) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

OCX:USA

Address

15 Cushing, Irvine, CA, USA, 92618

Website

https://www.oncocyte.com

OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through the United States.

OncoCyte (FRA:7OC0) Headlines

No Headlines